TAMIFLU CAPSULE 30MG

Product Information

Registration Status: Active

TAMIFLU CAPSULE 30MG is approved to be sold in Singapore with effective from 2008-07-31. It is marketed by ROCHE SINGAPORE PTE LTD, with the registration number of SIN13506P.

This product contains Oseltamivir 30mg in the form of CAPSULE. It is approved for ORAL use.

This product is manufactured by F. Hoffmann-La Roche Ltd in UNITED STATES,Delpharm Milano S.r.l. in SWITZERLAND, andPatheon Manufacturing Services LLC in ITALY.

It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.

Oseltamivir

Description

An acetamido cyclohexene that is a structural homolog of sialic acid and inhibits neuraminidase. [PubChem]

Indication

Oseltamivir (Tamiflu) is for the treatment of uncomplicated acute illness due to influenza infection in patients 1 year and older who have been symptomatic for no more than 2 days. It is also used for the prophylaxis of influenza in adult patients and adolescents 13 years and older.

Mechanism of Action

Oseltamivir is an ethyl ester prodrug requiring ester hydrolysis for conversion to the active form, oseltamivir carboxylate. The proposed mechanism of action of oseltamivir is inhibition of influenza virus neuraminidase with the possibility of alteration of virus particle aggregation and release.

Pharmacokinetics

Absorption
Readily absorbed from the gastrointestinal tract after oral administration with a bioavailability of 75%.
Distribution
* 23 to 26 L
Metabolism
Extensively converted to oseltamivir carboxylate by esterases located predominantly in the liver. Neither oseltamivir nor oseltamivir carboxylate is a substrate for, or inhibitor of, cytochrome P450 isoforms. At least 75% of an oral dose reaches the systemic circulation as oseltamivir carboxylate.
Elimination

Toxicity

At present, there has been no experience with overdose. Single doses of up to 1000 mg of oseltamivir have been associated with nausea and/or vomiting. Mean LD (intravenous, mouse) = 100 mg/kg.

Active Ingredient/Synonyms

(−)-oseltamivir | 1-Cyclohexene-1-carboxylic acid, 4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-, ethyl ester, (3R-(3alpha,4beta,5alpha))- | Ethyl (3R,4R,5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate | Oseltamivir | oséltamivir | Oseltamivirum | Oseltamivir |


Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.

References

  1. Health Science Authority of Singapore - Reclassified POM
  2. Drugbank